Paternal Valproate Use Not Linked to Child Development Issues
⚠️ Pregnancy-related topic: medication, diet, and testing decisions must be made with your obstetrician and neurology team.
Source: BMJ (JNNP)
Summary
Researchers studied the potential risks of neurodevelopmental disorders (NDDs) in children whose fathers used valproate, a medication often prescribed for epilepsy, during the time they were producing sperm. The study included data from Sweden and Norway, focusing on live births from 2007 to 2020. They compared children whose fathers took valproate with those whose fathers took other epilepsy medications, lamotrigine or levetiracetam.
The key finding of the study was that there was no significant increase in the risk of NDDs in children whose fathers used valproate compared to those whose fathers used lamotrigine or levetiracetam. This included conditions like autism spectrum disorder, attention-deficit/hyperactivity disorder, and intellectual disabilities. The results were consistent even when looking at different doses of the medication and among fathers who had epilepsy.
This study is important because it suggests that current concerns about the risks of paternal valproate use during sperm production may need to be reconsidered. However, it is essential to note that while the study was large and included data from two countries, it may not cover all possible factors that could influence the development of NDDs. More research is needed to fully understand the long-term effects of paternal medication use on children's health.
Free: Seizure First Aid Quick Guide (PDF)
Plus one plain-language weekly digest of new epilepsy research.
Unsubscribe anytime. No medical advice.
